Open for inclusion

A Phase 1, Open-label, Dose-Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Cancer type: Leukemia

Phase: I

Principal Investigator: Gjertsen Bjørn Tore

Country: NO

Keywords: Norway, Bergen, CC-90009-AML-01

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02848001?term=CC90009-AML&rank=1